ストックスクリーナーアプリを入手
40.32
0.44%
0.23
Mbx Biosciences Inc (MBX) 最新ニュース
MBX Biosciences shares fall despite positive one-year trial results for Canvuparatide (MBX) - MSN
How Do MBX Biosciences’ (MBX) Phase 2 Results Reframe Its Long-Term Hypoparathyroidism Strategy? - Yahoo Finance
Mizuho Securities Maintains MBX Biosciences(MBX.US) With Buy Rating, Maintains Target Price $57 - Moomoo
Health Care Roundup: Market Talk - Moomoo
MBX News | MBX BIOSCIENCES INC (NASDAQ:MBX) - ChartMill
MBX Biosciences, Inc. Common Stock (NASDAQ: MBX) Share Price, MBX Stock News, MBX Share Price & Updates - Kalkine
Mbx Biosciences90% of Patients in Ole Rema - Moomoo
MBX's Flagship Drug Trial Met Expectations But Perhaps Some Investors Wanted More -- Market Talk - Moomoo
Street canvu MBX phase II HP data more than one way - BioWorld News
MBX: Once-weekly kanvuparatide maintained durable efficacy and safety at one year, supporting phase III plans - TradingView
MBX reports one-year data for hypoparathyroidism drug candidate - Investing.com UK
MBX updates trial data for hypoparathyroidism drug (MBX:NASDAQ) - Seeking Alpha
MBX Biosciences, Inc. (MBX) Discusses One-Year Data From Phase II Open-Label Extension Study of Once-Weekly CanvuparatideSlideshow (NASDAQ:MBX) 2026-06-12 - Seeking Alpha
Transcript : MBX Biosciences, Inc.Special Call - marketscreener.com
MBX Biosciences Shares Fall Despite Positive One-Year Trial Results for Canvuparatide (MBX) - Yahoo Finance
MBX Biosciences reports positive one-year canvuparatide data - grafa.com
MBX Biosciences stock falls despite one-year drug trial data - Investing.com UK
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
MBX Biosciences' Phase 2 Trial of Canvuparatide Meets Primary Endpoint; Shares Drop Pre-Bell - marketscreener.com
MBX reports one-year data for hypoparathyroidism drug candidate By Investing.com - Investing.com Canada
MBX: Once-weekly canvuparatide maintained efficacy and safety at one year in chronic HP patients - TradingView
MBX Biosciences (Nasdaq: MBX) touts one-year canvuparatide data, plans Phase 3 - Stock Titan
Mbx Biosciences Announces One-Year Data Demonstrating Sustained Benefit Of Once-Weekly Canvuparatide As A Potential Pth Replacement Therapy In Chronic Hypoparathyroidism - TradingView
MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism - The Manila Times
Once-weekly PTH drug from MBX maintained calcium and kidney measures for a year - Stock Titan
Richard B. Bartram (MBX) plans sale of 9,167 shares after option exercise - Stock Titan
MBX (NASDAQ: MBX) Richard Bartram lists multiple May sales, June option exercise - Stock Titan
MBX Biosciences (MBX) director granted 12,500 stock options at $30.91 strike - Stock Titan
MBX Biosciences, Inc. Files Form 8-K with SEC Detailing Company Information and Stock Registration on NASDAQ - Minichart
MBX Biosciences Shareholders Approve Directors and Auditor - TipRanks
MBX Biosciences: In Danger Of Being Outpaced By RivalsRating Downgrade (NASDAQ:MBX) - Seeking Alpha
MB elects two Class II directors to three-year terms through 2029 - TradingView
MBX Biosciences (MBX) grants stock options to director Ora Pescovitz - Stock Titan
MBX Biosciences (MBX) director and 10% owner receives 12,500 stock options grant - Stock Titan
MBX Biosciences (MBX) director receives stock options for 12,500 shares - Stock Titan
MBX Biosciences (MBX) director receives grant of 12,500 stock options at $30.91 - Stock Titan
MBX Biosciences (MBX) director Steven Ryder granted 12,500 stock options - Stock Titan
MBX Biosciences (MBX) director awarded 12,500 stock options - Stock Titan
MBX Biosciences (NASDAQ: MBX) 2026 meeting backs directors and Ernst & Young - Stock Titan
Should Upcoming Canvuparatide Phase 2 Data Presentations Require Action From MBX Biosciences (MBX) Investors? - Sahm
MBX: Once-weekly PTH and monthly obesity therapies show strong promise for efficacy, tolerability, and market impact - TradingView
MBX Biosciences, Inc. partners with HypoPARAassoc to advance treatment for over 100,000 hypoparathyroidism patients in U.S. - Traders Union
MBX Biosciences to Host Virtual Investor Event to Discuss Once-Weekly Canvuparatide Presentations at ENDO 2026 - The Manila Times
MBX Biosciences to host webcast on Phase 2 trial results of once-weekly canvuparatide at ENDO 2026 - Pluang
Number of shareholders of MBX Biosciences, Inc. – NASDAQ:MBX - TradingView
Chief Medical Officer Sells MBX for $2.7 Million After Monster 2026 Run - AOL.com
3 Overlooked Stocks Set to Soar in 2026 - AOL.com
MBX Biosciences, Inc. executives to update on endocrine and metabolic disorder treatment advancements in New York - Traders Union
MBX Biosciences to Present at the Jefferies 2026 Global Healthcare Conference in New York City - GlobeNewswire
MBX Biosciences Inc Share News (MBX) - Investing.com India
MBX Biosciences Inc. (MBX) Q1 2026 Earnings: EPS Beat as Pre-Revenue Biotech Advances PipelineProfit Warning Alert - Newser
MBX Technical Analysis | Trend, Signals & Chart Patterns | MBX BIOSCIENCES INC (NASDAQ:MBX) - ChartMill
MBX Biosciences, Inc. thanks clinical trial participants as new therapies progress - Traders Union
MBX Biosciences (MBX) price target increased by 11.23% to 69.55 - MSN
LifeSci Capital Maintains MBX Biosciences(MBX.US) With Buy Rating, Raises Target Price to $91 - Moomoo
Insider Stock Buying Reaches US$1.06m On MBX Biosciences - Yahoo Finance
MBX Biosciences Advances Obesity And PBH Pipeline As Shares Surge - Sahm
1.79%
0.89%
大文字化:
|
ボリューム (24 時間):